deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT01223248

Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

A Phase III Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy in Patients With Metastatic Cancer

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Bone CNS-Spinal CD/MEMBR, NOS Lymph Nodes Melanoma Ovarian Cancer Sarcoma Soft Tissue
Interventions IGIMRT 27 Gy in 3 fractions IGIMRT using a single dose of 24 Gy
Updated 16 times since 2017 Last updated: Nov 3, 2025 Started: Oct 31, 2010 Primary completion: Oct 31, 2026 Completion: Oct 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Bone and CNS-Spinal CD/MEMBR, NOS, this trial is ongoing. The trial is conducted by Memorial Sloan Kettering Cancer Center and has accumulated 16 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Jul 2019 · 12 months · monthly snapshot~Jul 2019 – ~May 2020 · 10 months · monthly snapshot~May 2020 – ~Dec 2020 · 7 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Dec 2023 · 12 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Dec 2025 · 12 months · monthly snapshot~Dec 2025 – present · 9 months · monthly snapshot

Change History

16 versions recorded

  1. Dec 2025 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Dec 2024 — Dec 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Dec 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 11 earlier versions

  1. Dec 2022 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

  2. Dec 2021 — Dec 2022 [monthly]

    Active Not Recruiting PHASE3

  3. Jan 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  5. May 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Jul 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Jul 2018 — Jul 2019 [monthly]

    Active Not Recruiting PHASE3

  8. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  9. Jul 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  10. Feb 2017 — Jul 2017 [monthly]

    Active Not Recruiting PHASE3

  11. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
  • The Champalimaud Centre, Lisbon, Portugal
  • University of California, San Francisco
  • University of Pisa
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations